A phase II study assessing the intracranial response to nivolumab and nivolumab combined with ipilimumab in patients with melanoma brain metastases

Trial Profile

A phase II study assessing the intracranial response to nivolumab and nivolumab combined with ipilimumab in patients with melanoma brain metastases

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Brain metastases; Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms ABC Trial
  • Most Recent Events

    • 28 Aug 2017 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
    • 28 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.
    • 06 Jun 2017 Results (n=66) assessing antitumour activity and safety, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top